Roxadustat before off-pump bypass surgery to study heart muscle injury
Tests roxadustat given before bypass surgery in adults with coronary artery disease.
Plain-language title generated from the registry record
Registry title: Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 4
Where in China
- Peking University First HospitaBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT07912801
- Record updated
- 6 November 2026
- Original description
Myocardial injury and infarction are common after cardiac surgery and are associated with worse perioperative outcomes. Hypoxia-inducible factor (HIF) is an important metabolic regulator that protects the myocardium. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved for the treatment of anemia of chronic kidney disease; it enhances the hypoxia-protective pathway and erythropoiesis. The investigators hypothesize that, in patients undergoing off-pump coronary artery bypass grafting (CABG), preoperative treatment with roxadustat may reduce postoperative myocardial injury or infarction. This pilot study is designed to test the feasibility of conducting a large randomized trial and to provide preliminary data on the potential effect of roxadustat on the occurrence of myocardial injury or infarction in patients undergoing off-pump CABG.Read full original descriptionShow less
Effect of Preoperative Roxadustat on Myocardial Injury After Off-Pump Coronary Artery Bypass Graft Surgery: A Pilot Randomized Trial
Myocardial injury and infarction are common after cardiac surgery and are associated with worse perioperative outcomes. Hypoxia-inducible factor (HIF) is an important metabolic regulator that protects the myocardium. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved for the treatment of anemia of chronic kidney disease; it enhances the hypoxia-protective pathway and erythropoiesis. The investigators hypothesize that, in patients undergoing off-pump coronary artery bypass grafting (CABG), preoperative treatment with roxadustat may reduce postoperative myocardial injury or infarction. This pilot study is designed to test the feasibility of conducting a large randomized trial and to provide preliminary data on the potential effect of roxadustat on the occurrence of myocardial injury or infarction in patients undergoing off-pump CABG.
Inclusion: Age ≥45 years; Scheduled for off-pump coronary artery bypass grafting (CABG); Preoperative anemia, defined as hemoglobin <130 g/L in men or <120 g/L in women.
Exclusion: Current erythropoietin therapy; Diagnosis of cancer; Preoperative myocardial injury with high-sensitivity cardiac troponin I (hs-cTnI) still rising or not yet decreased to <10 times the upper reference limit; Severe hepatic impairment (Child-Pugh class C); Stage 5 chronic kidney disease requiring dialysis before surgery; Known allergy or hypersensitivity to roxadustat; Any other condition that, in the judgment of the investigator or treating physician, would make participation inappropriate; ASA physical status > IV.